Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.

Yvonne M. Saenger,Jay Magidson,Bobby Chi-Hung Liaw,Karl Wassmann,William Barker,Sara Harcharik,David E. Fisher,William Oh,Philip Friedlander

Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.

2017

Yvonne M. Saenger
Jay Magidson
Bobby Chi-Hung Liaw
Karl Wassmann
William Barker
Sara Harcharik
David E. Fisher
William Oh
Philip Friedlander

9080 Background: Tremelimumab (Ticilimumumab, Pfizer), a monoclonal antibody targeting CTLA-4, a T cell inhibitory molecule, has shown activity in metastatic melanoma. Ipilimumab (Yervoy, BMS), ano...

Keywords:

Pathology
T cell
Cancer research
Monoclonal antibody
Ipilimumab
Tremelimumab
Melanoma
Messenger RNA
Medicine
in patient
metastatic melanoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations